Silvan Tuerkcan
Stock Analyst at JMP Securities
(3.18)
# 1,175
Out of 4,984 analysts
169
Total ratings
46.06%
Success rate
1.53%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $23.60 | +44.07% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $24.62 | +82.82% | 2 | Sep 8, 2025 | |
| EXEL Exelixis | Reiterates: Market Outperform | $50 | $40.71 | +22.82% | 23 | Jul 29, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $70 → $12 | $2.35 | +410.64% | 6 | Jul 8, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $59.36 | +44.88% | 16 | Jun 27, 2025 | |
| NUVB Nuvation Bio | Reiterates: Market Outperform | $6 | $3.31 | +81.27% | 3 | Jun 25, 2025 | |
| SLDB Solid Biosciences | Reiterates: Market Outperform | $15 | $5.59 | +168.34% | 3 | Jun 6, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $5 → $6 | $2.92 | +105.48% | 13 | May 29, 2025 | |
| PRME Prime Medicine | Maintains: Market Outperform | $10 → $6 | $4.72 | +27.12% | 3 | May 20, 2025 | |
| BNTC Benitec Biopharma | Reiterates: Market Outperform | $20 | $13.71 | +45.93% | 12 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $4.87 | +84.80% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $6 | $1.51 | +298.67% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $6.30 | +185.71% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $20 | $7.51 | +166.31% | 12 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.57 | +982.80% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $5.82 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $0.86 | +363.77% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $4.13 | +408.47% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.54 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.07 | +95.44% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $190.43 | +47.04% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $10.05 | +79.10% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.54 | - | 10 | Jan 19, 2023 |
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $23.60
Upside: +44.07%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $24.62
Upside: +82.82%
Exelixis
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $40.71
Upside: +22.82%
Jasper Therapeutics
Jul 8, 2025
Maintains: Market Outperform
Price Target: $70 → $12
Current: $2.35
Upside: +410.64%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $59.36
Upside: +44.88%
Nuvation Bio
Jun 25, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $3.31
Upside: +81.27%
Solid Biosciences
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $5.59
Upside: +168.34%
Taysha Gene Therapies
May 29, 2025
Maintains: Market Outperform
Price Target: $5 → $6
Current: $2.92
Upside: +105.48%
Prime Medicine
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $4.72
Upside: +27.12%
Benitec Biopharma
May 15, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $13.71
Upside: +45.93%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $4.87
Upside: +84.80%
May 9, 2025
Downgrades: Market Perform
Price Target: $6
Current: $1.51
Upside: +298.67%
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $6.30
Upside: +185.71%
Apr 21, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $7.51
Upside: +166.31%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.57
Upside: +982.80%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $5.82
Upside: -
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $0.86
Upside: +363.77%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $4.13
Upside: +408.47%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.54
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $3.07
Upside: +95.44%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $190.43
Upside: +47.04%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $10.05
Upside: +79.10%
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $12.54
Upside: -